The Froedtert & Medical College of Wisconsin health network selects RayStation
RaySearch Laboratories AB (publ) announces that the Froedtert & Medical College of Wisconsin health network, USA, has placed an order for the treatment planning system RayStation®*. The order was received and delivered in the fourth quarter, 2023.
The Froedtert & MCW health network has purchased RayStation for photon treatments on its Elekta linear accellerators and the Accuray Radixact® treatment delivery system, as well as hyperscanning proton licenses for the health network's upcoming Mevion S250i proton therapy system. Additional licenses were purchased for deformable registration, fallback planning, dose tracking, adaptive planning and the newly released ability to perform LET optimization for proton therapy. The health network's cancer specialists will also be able to use AI segmentation to prepare patients for planning.
The Froedtert & MCW health network offers a nationally and internationally recognized premier cancer program with six cancer centers anchored by the only academic medical center in eastern Wisconsin. The Clinical Cancer Center at the health network's Froedtert Hospital campus anticipates being the first center in Wisconsin to offer proton therapy.
Eric Smith, Director of Radiation Oncology for the Froedtert & MCW health network and for the health network's cancer center at Holy Family Memorial Hospital in Manitowoc, Wisconsin, says: “This is a new era for our organization. We are pleased to partner with RaySearch Laboratories to bring RayStation for the benefit of our patients. The ability to use RayStation to plan treatment for our conventional linear accelerators and our proton therapy system in the future, will provide practical and financial efficiencies, as well as the opportunity to deliver the best treatment plans possible."
Johan Löf, founder and CEO, RaySearch, says: “The Froedtert & MCW health network is an excellent example of the kind of health system that will enjoy the maximum benefit from RaySearch's technologies. RayStation's support for multiple delivery systems makes implementation easier and more effective at many levels. The medical staff will be able to use a single platform and determine the ideal treatment modality for every cancer patient. We look forward to working with the Froedtert & MCW cancer team for many years to come.”
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch's software has been sold to over 900 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
About RayStation
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.
* Subject to regulatory clearance in some markets.
Tags:
